Laurel A. Habel, PhD

A multigene test for breast cancer recurrence risk was used in a minority of eligible patients, yet was associated with a decrease in chemotherapy use.

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

Although we found no DCIS treatment disparities by race/ethnicity, use of adjuvant radiation therapy was less among older women and among residents of poorer neighborhoods.